Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Health sciences. The field of gene therapy has made prominent progress in the past three decades, surging from mere laboratory experiments to US Food and Drug Administration (FDA)-approved products. This has brought significant reduction in disease burden to the patients who previously had no therapeutic options. Gene therapy is probably the most compelling area of biotechnology at this moment-both due to the recent progress and because of the possibilities on the horizon. Unprecedented levels of control over nucleic acid delivery, modulation of the immune system, and precise manipulation of the human genome – technologies not imaginable ten years ago – will certainly unlock new areas of medicine over the next ten years. Despite the limited number of products successfully reaching the market, the number of clinical trials investigating gene therapies is increasing worldwide. The main barrier to gene therapy is the cost and affordability of the drug product and the high prices for curative genetic treatment may limit access to the treatment and thus reduce or hinder the therapy’s advantage over current treatment choices.
Through Gene therapies whitepaper, DelveInsight will draw your attention towards the current picture of Next generation gene therapies along with its types and the gene therapy regulations. The whitepaper summarizes the gene therapies being developed across several therapeutic areas including rare diseases, genetic disorders, oncology and several other areas. This paper also highlights the challenges being faced in the development for gene therapies. In addition, the reader can get an ongoing scenario and the future of gene therapies in development.